Evidence map›Paper›PMID 26657156›Full record

ArticleOncogene2016

CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells.

Y Zhao, D Masiello, M McMillian, C Nguyen, Y Wu, E Melendez, G Smbatyan, A Kida, Y He, J-L Teo and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Targeting CBP and p300: Emerging Anticancer Agents.Molecules (Basel, Switzerland) · 2024
    Review
  5. Review
  6. Review
  7. Article
  8. Re-Sensitizing Cancer Stem Cells to Conventional Chemotherapy Agents.International journal of molecular sciences · 2023
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Y ZhaoDepartment of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
D MasielloCenter for Molecular Pathways and Drug Discovery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
M McMillianNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
C NguyenNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Y WuCenter for Molecular Pathways and Drug Discovery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
E MelendezNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
G SmbatyanNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
A KidaCenter for Molecular Pathways and Drug Discovery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Y HeCenter for Molecular Pathways and Drug Discovery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
J-L TeoNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
M KahnNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Pathways Behavioral Services · USUniversity of Southern California · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Efficacy of Novel Wnt Modulator in Colon CancerR01CA166161 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KAHN, MICHAEL, LENZ, HEINZ JOSEF · 2013 to 2017
$2.3M
Mechanisms of beta-catenin signaling in alveolar epithelial cell differentiationR01HL112638 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BOROK, ZEA, KAHN, MICHAEL · 2013 to 2016
$2.2M
NCI NIH HHS P30 CA014089NCI NIH HHS R01 CA166161NHLBI NIH HHS R01 HL112638
6 · The paper itself

Abstract

CREB-binding protein (CBP) and p300 are highly homologous transcriptional coactivators with unique, non-redundant roles that bind a wide array of proteins, including catenins-β and γ. ICG-001 is a small-molecule inhibitor that specifically inhibits the CBP/catenin interaction. Importantly, ICG-001 does not inhibit the p300/catenin interaction. We demonstrate that specifically inhibiting the interaction between CBP and catenin with ICG-001 results in the differentiation of quiescent drug-resistant chronic myelogenous leukemia-initiating cells (CML LICs), thereby sensitizing them to BCR-ABL tyrosine kinase inhibitors, for example, Imatinib. Using ICG-001 in a NOD/SCID/IL2Rγ(-/-) mouse model of engrafted human chronic myelogenous leukemia, we now demonstrate the complete elimination of engrafted leukemia after only one course of combined chemotherapy. Combination-treated animals live as long as their non-engrafted littermates. Results from these studies demonstrate that specifically antagonizing the CBP/catenin interaction with ICG-001 can eliminate drug-resistant CML LICs without deleterious effects to the normal endogenous hematopoietic stem cell population.

Indexed as

AnimalsBridged Bicyclo Compounds, HeterocyclicCateninsCell Line, TumorCREB-Binding ProteinDrug Resistance, NeoplasmE1A-Associated p300 ProteinFemaleFusion Proteins, bcr-ablHumansImmunoblottingInterleukin Receptor Common gamma SubunitK562 CellsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMice, Inbred NODMice, KnockoutBridged Bicyclo Compounds, HeterocyclicCateninsCREB-Binding ProteinCREBBP protein, humanE1A-Associated p300 ProteinEP300 protein, humanFusion Proteins, bcr-ablICG 001Il2rg protein, mouseInterleukin Receptor Common gamma SubunitPyrimidinones

Identifiers

PMID26657156
PMCPMC5526055
OpenAlexW2195303060

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.